Document is current
Any future updates will be listed below
-
Authors
Knapskog, Anne-Brita
Edwin, Trine Holt
Ueland, Per Magne
Ulvik, Arve
Fang, Evandro Fei
Eldholm, Rannveig Sakshaug
Halaas, Nathalie Bodd
Giil, Lasse M.
Saltvedt, Ingvild
Watne, Leiv Otto
Aksnes, Mari
-
Funding
Funding for this research was provided by:
Nasjonalforeningen for Folkehelsen,Norway (22679)
Nasjonalforeningen for Folkehelsen,Norway (22679)
Nasjonalforeningen for Folkehelsen,Norway (25633)
Wellcome Leap (104617)
Wellcome Leap (104617)
Cure Alzheimer's Fund (282952)
Helse Sør-Øst RHF (2020001)
Helse Sør-Øst RHF (2017095)
Norges Forskningsråd (262175)
Norges Teknisk-Naturvitenskapelige Universitet (334361)
VitaDAO, Canada (282942)
NordForsk,Norway (119986)
National Natural Science Foundation of China (81971327)
Akershus Universitetssykehus (269901; 261973; 262960)
Civitan Norges Forskningsfond for Alzheimers sykdom, Norway (281931)
Czech Republic-Norway KAPPA programme, Czech Republic (TO01000215)
Kreftforeningen (207819)
University of Oslo
- License Information
-
More Information
Article History
Received: 23 April 2024
Accepted: 15 July 2024
First Online: 27 July 2024
Declarations
:
: All patients and controls gave their informed written consent for participation in line with the Declaration of Helsinki. This study was approved by the Norwegian Regional Committees for Medical and Health Research Ethics (REC South East, 2017/371 and 2011/2052) and the Data Protector Officer at Oslo University Hospital.
: A.B.K. has been principal investigator on the Roche drug trial BN29553, on the Boehringer-Ingelheim drug trial 1346.0023, and the Novo Nordisk drug trial NN6535-4730. T.H.E. has been investigator on the clinical trial Roche BN29553; and T.H.E. and I.S. have worked on the Boehringer-Ingelheim clinical trial 1346.0023. E.F.F. is the co-owner of Fang-S Consultation AS (Organization number 931 410 717); he has an MTA with LMITO Therapeutics Inc (South Korea), a CRADA arrangement with ChromaDex (USA), a commercialization agreement with Molecule AG/VITADAO; he is a consultant to Aladdin Healthcare Technologies (UK and Germany), the Vancouver Dementia Prevention Centre (Canada), Intellectual Labs (Norway), MindRank AI (China), NYO3 (Norway and China), and Epivity Health (Norway). The other authors declare that they have no competing interests.
